Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax and Azacitidine for ETP-ALL and T-ALL with Myeloid Mutations
NCT07012447Phase 2Recruiting
- Start
- Apr 2025
- Primary completion
- Apr 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of venetoclax in Early T-cell precursor acute lymphoblastic leukemia (ETP-ALL), t-cell acute lymphoblastic leukemia (T-ALL) and mixed phenotype acute leukemia (MPAL). Primary endpoint: Overall Response Rate at 100 days. Started Apr 2025; status: recruiting.
02
Drugs
venetoclax
03
Conditions
Early T-cell precursor acute lymphoblastic leukemia (ETP-ALL)t-cell acute lymphoblastic leukemia (T-ALL)mixed phenotype acute leukemia (MPAL)
Beyond the preview
Go deeper on NCT07012447.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07012447.